final sub-cloned hybridoma (Absolute Biotech Inc)
90
Structured Review
Absolute Biotech Inc
final sub-cloned hybridoma
Final Sub Cloned Hybridoma, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/final+sub-cloned+hybridoma/final+sub+cloned+hybridoma/pmc09563779-76-13-16
Average 90 stars, based on 1 article reviews
Final Sub Cloned Hybridoma, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/final+sub-cloned+hybridoma/final+sub+cloned+hybridoma/pmc09563779-76-13-16
Average 90 stars, based on 1 article reviews
final sub-cloned hybridoma - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform"
Article Title: Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform
Journal: Cancers
doi: 10.3390/cancers14194859
Figure Legend Snippet: p95HER2 poly and monoclonal hybridoma selection. ( a ) The top nine polyclonal hybridomas from the initial iQue screening were tested by flow cytometry for binding to breast cancer target cells expressing 611-p95HER2 (p95HER2−-T47D) or full-length HER2 (SK-BR-3), and HER2 negative controls including wild type T-47D and SUP-T1 (blue: secondary antibody alone and red: secondary + primary antibodies). pClone 2 had the strongest p95HER2-reactivity, followed by pClones 1, 3 and 8. pClones 2 and 8 were weekly reactive to SK-BR-3 (HER2+), while pClone 1 and 3 had no detectable reactivity against SK-BR-3. None of the pClones were reactive to the HER2 negative target cells (T-47D or SUP-T1). ( b ) Flow cytometry screening of supernatants from monoclonal hybridomas (mClones) generated from pClones 1, 2 and 3. mClone 1 stained p95HER-T47D, and not SK-BR-3. mClone 2 stained both p95HER-T47D and SK-BR-3, while mClone 3 stained neither. ( c ) The same batch of p95HER-T47D cells was stained for immunofluorescence with supernatants from pClone 1 and mClone 1. These results indicate that the reactivity of Clone 1 to p95HER2 was increased from the poly- to monoclonal level.
Techniques Used: Selection, Flow Cytometry, Binding Assay, Expressing, Generated, Staining, Immunofluorescence
Related Articles
Sequencing:Article Title: Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform Article Snippet: Hybridoma sequencing, mAb production and purification: High-throughput sequencing was performed on a final Purification:Article Title: Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform Article Snippet: Hybridoma sequencing, mAb production and purification: High-throughput sequencing was performed on a final Next-Generation Sequencing:Article Title: Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform Article Snippet: Hybridoma sequencing, mAb production and purification: High-throughput sequencing was performed on a final cDNA Library Assay:Article Title: Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform Article Snippet: Hybridoma sequencing, mAb production and purification: High-throughput sequencing was performed on a final Generated:Article Title: Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform Article Snippet: Hybridoma sequencing, mAb production and purification: High-throughput sequencing was performed on a final Selection:Article Title: Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform Article Snippet: Hybridoma sequencing, mAb production and purification: High-throughput sequencing was performed on a final Flow Cytometry:Article Title: Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform Article Snippet: Hybridoma sequencing, mAb production and purification: High-throughput sequencing was performed on a final Binding Assay:Article Title: Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform Article Snippet: Hybridoma sequencing, mAb production and purification: High-throughput sequencing was performed on a final Expressing:Article Title: Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform Article Snippet: Hybridoma sequencing, mAb production and purification: High-throughput sequencing was performed on a final Staining:Article Title: Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform Article Snippet: Hybridoma sequencing, mAb production and purification: High-throughput sequencing was performed on a final Immunofluorescence:Article Title: Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform Article Snippet: Hybridoma sequencing, mAb production and purification: High-throughput sequencing was performed on a final |